Alzheimer’s Benefits Continue With Donanemab for 3 Years, Long-Term Data Show

By News Health
12 hours Ago

(MedPage Today) — TORONTO — The clinical benefits of donanemab (Kisunla) continued over 3 years in people with early symptomatic Alzheimer’s disease, data from the long-term extension of the TRAILBLAZER-ALZ 2 trial suggested.
Compared with…

Source link : https://www.medpagetoday.com/meetingcoverage/aaic/116791

Author :

Publish date : 2025-08-01 18:42:00

Copyright for syndicated content belongs to the linked Source.

Categories: Health News

Related Content

Major Medical Groups Pushed Out of Role Supporting CDC's Vaccine Advisors

'It's Gonna Be (Ly)me': Justin Timberlake Brings Attention, Awareness to Disease

ACOG No Longer Accepting Federal Funding, Citing Policy Disputes

States Sue Trump, Say Targeting of Hospitals Over Gender Care in Minors Is Unlawful

Time Your Meals, Tune Your Metabolism

Novel Eye Drops for Age-Related Blurry Vision Win FDA Approval